Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)

Followers: 0

Organization

Health Canada | Santé Canada

There is no description for this organization

License

ca-ogl-lgo

Activity type

db7b3e1b-b274-4c52-92e9-2a2a98b46cf1 created the dataset Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)
3 months ago

Newer activities Older activities